Cargando…
Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity
Small molecules that selectively kill senescent cells (SCs), termed senolytics, have the potential to prevent and treat various age-related diseases and extend healthspan. The use of Bcl-xl inhibitors as senolytics is largely limited by their on-target and dose-limiting platelet toxicity. Here, we r...
Autores principales: | He, Yonghan, Zhang, Xuan, Chang, Jianhui, Kim, Ha-Neui, Zhang, Peiyi, Wang, Yingying, Khan, Sajid, Liu, Xingui, Zhang, Xin, Lv, Dongwen, Song, Lin, Li, Wen, Thummuri, Dinesh, Yuan, Yaxia, Wiegand, Janet S., Ortiz, Yuma T., Budamagunta, Vivekananda, Elisseeff, Jennifer H., Campisi, Judith, Almeida, Maria, Zheng, Guangrong, Zhou, Daohong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7181703/ https://www.ncbi.nlm.nih.gov/pubmed/32332723 http://dx.doi.org/10.1038/s41467-020-15838-0 |
Ejemplares similares
-
Assays and technologies for developing proteolysis targeting chimera degraders
por: Liu, Xingui, et al.
Publicado: (2020) -
Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
por: He, Yonghan, et al.
Publicado: (2020) -
PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics
por: Khan, Sajid, et al.
Publicado: (2020) -
DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas
por: He, Yonghan, et al.
Publicado: (2020) -
Inhibition of USP7 activity selectively eliminates senescent cells in part via restoration of p53 activity
por: He, Yonghan, et al.
Publicado: (2020)